| __timestamp | BioCryst Pharmaceuticals, Inc. | Pfizer Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 51796000 | 8393000000 |
| Thursday, January 1, 2015 | 72758000 | 7690000000 |
| Friday, January 1, 2016 | 61008000 | 7872000000 |
| Sunday, January 1, 2017 | 66962000 | 7657000000 |
| Monday, January 1, 2018 | 84888000 | 8006000000 |
| Tuesday, January 1, 2019 | 107068000 | 8650000000 |
| Wednesday, January 1, 2020 | 122964000 | 9405000000 |
| Friday, January 1, 2021 | 208808000 | 13829000000 |
| Saturday, January 1, 2022 | 253297000 | 11428000000 |
| Sunday, January 1, 2023 | 216566000 | 10679000000 |
| Monday, January 1, 2024 | 10930000000 |
Unleashing insights
In the ever-evolving pharmaceutical landscape, research and development (R&D) budgets are pivotal. Over the past decade, Pfizer Inc. and BioCryst Pharmaceuticals, Inc. have showcased contrasting R&D strategies. Pfizer, a global leader, consistently allocated substantial resources, with its R&D expenses peaking at approximately $13.8 billion in 2021. This represents a 65% increase from 2014, underscoring its commitment to innovation.
Conversely, BioCryst, a smaller player, demonstrated a more modest yet significant growth in R&D spending. From 2014 to 2023, its budget surged by over 300%, reaching around $253 million in 2022. This growth highlights BioCryst's strategic focus on niche markets and specialized treatments.
These trends reflect broader industry dynamics, where large firms leverage scale, while smaller companies capitalize on agility and specialization. As the pharmaceutical sector continues to innovate, these R&D investments will shape the future of healthcare.
Who Prioritizes Innovation? R&D Spending Compared for Pfizer Inc. and Grifols, S.A.
R&D Insights: How Pfizer Inc. and TG Therapeutics, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Pfizer Inc. and Protagonist Therapeutics, Inc.
Pfizer Inc. or Amphastar Pharmaceuticals, Inc.: Who Invests More in Innovation?
R&D Insights: How Pfizer Inc. and Novavax, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Incyte Corporation and BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc.
Research and Development Investment: Ascendis Pharma A/S vs BioCryst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Rhythm Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for PTC Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc.
Protagonist Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: MannKind Corporation vs BioCryst Pharmaceuticals, Inc.